WELCOME TO iGEM 2014!

Your team has been approved and you are ready to start the iGEM season!
On this page you can document your project, introduce your team members, document your progress
and share your iGEM experience with the rest of the world!

Click here to edit this page!

Introduction

Project

Treating infectious diseases of the gastrointestinal (GI) tract with antibiotics disrupts a patient's gut microbiota and can increase the prevalence of antibiotic resistant strains. The increasing population of multi-drug resistant bacterial strains, both within and outside of health centers, is a growing health concern that is becoming progressively difficult to treat. Additionally, it is a well-recognized fact within the global health community that traditional antibiotics do not represent a sustainable method of treatment for bacterial infections. There is a clear drive towards minimally invasive, prophylactic therapies for such ailments, but is a demand that so far, has not been adequately met. Our project will aim at replacing broad and narrow spectrum antibiotics with “precision therapies” that have etiology targeting capacity at the species level as well as contain minimal cross-talk among healthy tissues, organs, and symbiotic organisms.

We envision a new paradigm for treating infections of the human gastrointestinal tract through exploitation of engineered probiotics that produce anti-microbials with high specificity for pathogens. The anti-microbials we are exploring do not utilize a one-fit all therapy mold, but target unique features specific to organisms at the genetic level. Towards this aim, we have utilized a general-purpose system that will be delivered to pathogenic bacteria from an engineered bacterial species found in the GI tract (Escherichia coli), which will cleave pathogenic genes with single nucleotide resolution. To achieve specific genome targeting, we will utilize the CRISPR/Cas9 system with gRNA engineered to recognize genes from infectious bacteria that contribute to pathogenicity in humans. Our CRISPR/Cas9 system will be delivered from the engineered E. coli to infectious bacteria using bacterial specific phages, minimizing any side-effects to native microbiota and human-host cells. As a proof-of-principle for our engineered probiotic, we are starting by targeting Vibrio cholerae, however we hope to expand the system to other pathogens of the GI tract.

References

iGEM teams are encouraged to record references you use during the course of your research. They should be posted somewhere on your wiki so that judges and other visitors can see how you though about your project and what works inspired you.

Use these links to navigate our project!

• History of Cholera
• Project Details
• Materials and Methods
• Results
• Conclusions

dfdfddf

It's also important to clearly describe your achievements so that judges will know what you tried to do and where you succeeded. Please write your project page such that what you achieved is easy to distinguish from what you attempted.